- With the renewal of this exclusive partnership, eurobio ingen, Diaxonhit’s commercial affiliate, confirms its commitment in France for diagnostic tests in transplantation
Paris, France – May 02, 2018 – Diaxonhit (FR0013240934, ALEHT, eligible PEA-PME), French market leader of in vitro medical diagnostics and life sciences, is pleased to announce that eurobio-ingen, its commercial subsidiary, has renewed, for a three-year period, its exclusive commercial partnership with One Lambda, a Thermo Fisher Scientific brand, for the commercialization of diagnostic tests for transplantation in France.
Today, eurobio ingen is the largest provider of diagnostic products to laboratories that are responsible for carrying out all tests related to transplantation in France. With a strong position in this sector, eurobio ingen and One Lambda have renewed this partnership which was established in 1996.
“The renewal of this partnership demonstrates the confidence of One Lambda in our marketing abilities. It enables our Group to strengthen its investment strategy over the long term in all areas of transplantation and particularly in Next Generation Sequencing” says Jacques Martin, head of eurobio ingen transplantation business unit.
One Lambda develops and distributes a comprehensive line of HLA1 typing tests utilizing both serological and molecular technologies, including Next Generation Sequencing. It also manufactures the most complete line of antibody detection products in the industry that have been designed to monitor patients both pre- and post-transplant. They are used to detect HLA antibodies that may cause graft rejection. In addition, One Lambda manufactures laboratory instrumentation, and computer software that are used to simplify and automate testing procedures and final test evaluations. With five different product lines, One Lambda offers transplant laboratories to choose a solution that best suits their needs.
HLA tests marketed by eurobio ingen are used to assess the compatibility between donor and recipient before transplantation, and to follow-up transplanted patients in order to monitor potential rejection and adjust immunosuppressive treatments accordingly. Before transplantation, HLA typing is performed routinely by serology or molecular biology, as well as detection of anti-HLA antibodies synonymous with increased risk of rejection. After transplantation, rejection is monitored with tests that identify anti-HLA antibodies present in patients. All these tests are performed in the HLA laboratories of the French Blood Bank, and in histocompatibility (immunology) laboratories of university hospitals.
The field of transplantation covers all activities related to organ and bone marrow transplants. In 2017, more than 6,100 transplants were performed in France2, up 19% over the last 5 years (2013-2017), with rejection remaining the main risk. The rates of acute rejection within a year after transplantation ranging from 5% (kidney) to 50% (lung)3, the need for reliable diagnostic tests is essential.
About One Lambda, Inc.
One Lambda, A Thermo Fisher Scientific Brand, is the worldwide leader in HLA typing and antibody detection assays. One Lambda is known for its commitment to quality, service, and innovation. The company develops and distributes several lines of HLA typing and antibody detection tests utilizing serological, molecular, ELISA, flow cytometry, and Luminex™ xMAP™ technologies. In addition, One Lambda also manufactures laboratory instrumentation and computer software that are used to simplify and automate testing procedures and final test evaluations.
For more information, please visit http://www.onelambda.com
Diaxonhit (ALEHT, Euronext Growth, FR0013240934) is a key player in the field of specialty in vitro diagnostics and life sciences. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, immunology and infectious diseases, and sells instruments and products for research laboratories in life-science, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Diaxonhit has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The Diaxonhit group, based in the Paris region and in the United States, has more than 120 employees. The company is publicly listed on the Euronext Growth market in Paris, and is part of the Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices.
This press release contains elements that are not historical facts including, without limitation, certain statements about future expectations and other forward-looking statements. Such statements are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated. In addition, Diaxonhit, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only. Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the English language version shall prevail.